胡正忠博士
- 菱電醫療控股有限公司首席執行官
- 熒康醫療創新有限公司聯合創始人兼首席醫療事務官
- 思維創投有限公司創始合伙人
- 約翰霍普金斯大學，組織工程和再生醫學博士
A translational biomedical engineer with a strong background in business development and investments, Charles’s vision is in bringing about a vibrant healthcare innovation and investment ecosystem in the HK Greater Bay Area. He obtained his PhD from Johns Hopkins University, BS from University of California, Berkeley, and his scientific expertise interfaces across biomedical engineering, regenerative medicine, interventional radiology, and materials science. He is also experienced in research commercialization and in MNC pharma product development and medical affairs. He co-founded Incando Therapeutics to bring innovative therapeutic technologies to the clinical stage and targeting difficult to treat diseases including recurrent cancer and neurodegenerative diseases. On the business front, Charles heads Ryoden Medical Holdings where he oversees healthcare venture investments for his family office, advises angel investors and startups, and actively engages in policy discussions in support of biomedical innovations and youth talent development.
Charles is an Adjunct Professor of Biomedical Sciences, Industrial Advisor of Biomedical Engineering, 30th Anniversary Steering Committee Member, and HK Tech 300 Selection Panelist at the City University of Hong Kong, vice president of the BIOHK international biotechnology conventions, board member of two biotechnology companies, council advisor to the Asian Fund for Cancer Research, member of the Hong Kong Professionals and Senior Executives Association (HKPASEA), and director of several retail, food & beverage, and real estate businesses. He was awarded the Outstanding Young Entrepreneur Award and Best Sci-Tech Innovation Project in 2023 by the Guangdong-HK-Macao Bay Area Entrepreneurs Union and the Chinese General Chamber of Commerce (“CGCC”) in Hong Kong.